These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38840331)

  • 1. Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study.
    Li P; Huang L; Han R; Tang M; Fei G; Zeng D; Wang R
    Clin Transl Med; 2024 Jun; 14(6):e1673. PubMed ID: 38840331
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
    Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
    Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
    Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
    Eur J Cancer; 2021 Mar; 145():179-182. PubMed ID: 33486441
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
    Jiang WR; Fang LP; Chang N; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
    Hosokawa S; Ichihara E; Bessho A; Harada D; Inoue K; Shibayama T; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 Feb; 51(2):279-286. PubMed ID: 33049757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; McCutcheon A; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Ann Oncol; 2019 Apr; 30(4):655-657. PubMed ID: 30753264
    [No Abstract]   [Full Text] [Related]  

  • 9. Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer.
    Shi X; Wang P; Li Y; Xu J; Yin T; Teng F
    Thorac Cancer; 2024 Mar; 15(9):738-748. PubMed ID: 38376861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
    Oyanagi J; Koh Y; Sato K; Teraoka S; Tokudome N; Hayata A; Akamatsu H; Ozawa Y; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2021 Nov; 22(6):e833-e841. PubMed ID: 34049821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
    Ahn BC; So JW; Synn CB; Kim TH; Kim JH; Byeon Y; Kim YS; Heo SG; Yang SD; Yun MR; Lim S; Choi SJ; Lee W; Kim DK; Lee EJ; Lee S; Lee DJ; Kim CG; Lim SM; Hong MH; Cho BC; Pyo KH; Kim HR
    Eur J Cancer; 2021 Aug; 153():179-189. PubMed ID: 34182269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.
    Gu Q; Feng Z; Liang Q; Li M; Deng J; Ma M; Wang W; Liu J; Liu P; Rong P
    Eur J Radiol; 2019 Sep; 118():32-37. PubMed ID: 31439255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in lung cancer: current status and future directions.
    Fan Y; Mao W
    Chin Clin Oncol; 2017 Apr; 6(2):17. PubMed ID: 28482670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.
    Chen C; Chen M; Bai Y; Li Y; Peng J; Yao B; Feng J; Zhou JG; Ma H
    Technol Cancer Res Treat; 2024; 23():15330338241249690. PubMed ID: 38706247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in circulating PD-1
    Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
    Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors 
of Small Cell Lung Cancer].
    Yang Y; Wang Y
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):897-903. PubMed ID: 32773012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
    Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
    Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.